The Mayo Clinic has launched CANCP, a 50-gene cancer panel that assesses hotspot mutations using next-generation sequencing with the goal of predicting a patient's response to therapy. The test is available to Mayo patients and providers worldwide through Mayo Medical Laboratories.


Oxford Gene Technology has launched SureSeq Solid Tumor Panel, a 60-gene cancer panel that uses hybridization-based enrichment and is assessed via next-generation sequencing. The panel was validated on formalin-fixed paraffin embedded tissue and covers the entire exons of the 60 genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.